We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Electronic Nose Accurately Diagnoses Prostate Tumor Using Urine Sample

By LabMedica International staff writers
Posted on 05 Dec 2022
Print article
Image: Prototype of an electronic nose capable of diagnosing tumor using urine sample (Photo courtesy of Polytechnic University of Milan)
Image: Prototype of an electronic nose capable of diagnosing tumor using urine sample (Photo courtesy of Polytechnic University of Milan)

The diagnosis of prostate cancer using a non-invasive method and with greater accuracy than traditional diagnostic procedures is ever closer to becoming a reality. This has been confirmed by the data in a study which tested the efficacy of the first prototype of an electronic nose that can identify the presence of a tumor from a urine sample, by recognizing specific volatile molecules.

Diag-Nose – the name of the project which created the first experimental prototype – is the result of close collaboration between Humanitas Mater Domini (Castellanza VA, Italy) and the Polytechnic University of Milan (Milan, Italy). The project involved 174 people divided into two groups: 88 patients with prostate cancer of varying grades and stages confirmed by a histological examination, and 86 people in the “control” group comprising men and women of different ages with no history of the disease who had undergone medical examinations (including for PSA). A urine sample was collected from each person and analyzed.

The preliminary results are encouraging. The electronic nose was found to correctly provide a positive result for patients with tumors in 85.2% of cases. It has an accuracy – that is the ability to make a correct diagnosis, whether negative or positive – of 82.1%. For men over the age of 45 only, the age range most affected by the disease but also the most difficult to correctly diagnose, the accuracy stands at 81%. The prototype has other significant benefits when compared to the traditional method of a biopsy: as well as being an invasive procedure, biopsies have a particularly high rate of false negatives for early-stage tumors due to the fact that only a small portion of tissue is collected and analyzed.

“Prostate biopsy is currently the gold standard for the diagnosis of cancer of this gland. Despite the greater precision that the procedure has achieved through the use of magnetic resonance imaging to guide the collection of the tissue samples, the tumor detection rate reaches 48.5% at the most. This percentage is significantly lower than that of the electronic nose which, in addition to greater diagnostic accuracy, would limit the inconvenience and complications for the patient”, explained the author of the study, Dr. Gianluigi Taverna, Urology Coordinator at Humanitas Mater Domini and a doctor-researcher at the Humanitas Research Hospital.

“For the electronic nose to effectively become a part of everyday clinical practice, further large-scale studies will be necessary, which will allow us to confirm the results already obtained and to develop the prototype's potential. Therefore, the next step towards making the electronic nose a reality is to validate it by involving international clinical institutes,” concluded Gianluigi Taverna and Fabio Grizzi, a researcher at the laboratories of the Humanitas Research Hospital, where he is also in charge of the histology service.

Related Links:
Polytechnic University of Milan
Humanitas Mater Domini 

HLX
Gold Supplier
PCR Microplate
SAPPHIRE MICROPLATE
New
Portable Coagulation Monitor
VCM
New
ELISA Kits
ALLERgen Specific IgE ELISA Kits

Print article

Channels

Clinical Chem.

view channel
Image: Electrochemical cells etched by laser on wooden tongue depressor measure glucose and nitrite in saliva (Photo courtesy of Analytical Chemistry)

Biosensor-Fabricated Wooden Tongue Depressor Measures Glucose and Nitrite in Saliva

Physicians often use tongue depressors to examine a patient's mouth and throat. However, it is hard to imagine that this simple wooden tool could actively assess a patient's health. This idea has led to... Read more

Molecular Diagnostics

view channel
Image: The Geo portable testing platform integrated with the Snap collection device (Photo courtesy of ReadyGo Diagnostics)

Ultra-Portable Rapid Test Platform Offers Complete Sample-to-Answer Solution for Remote and Off-Grid Testing

An ultra-portable isothermal molecular diagnostics system integrated with a patented device which combines sample collection and processing into a single, easy-to-use disposable is set to revolutionize... Read more

Hematology

view channel
Image: The Atellica HEMA 570 and 580 hematology analyzers remove workflow barriers (Photo courtesy of Siemens)

Next-Gen Hematology Analyzers Eliminate Workflow Roadblocks and Achieve Fast Throughput

Hematology testing is a critical aspect of patient care, utilized to establish a patient's health baseline, track treatment progress, or guide timely modifications to care. However, increasing constraints... Read more

Immunology

view channel
Image: Newly observed anti-FSP antibodies have also been found to predict immune-related adverse events (Photo courtesy of Calviri)

First Blood-Based Biomarkers Test to Predict Treatment Response in Cancer Patients

Every year worldwide, lung cancer afflicts over two million individuals and almost the same number of people succumb to the disease. This malignancy leads the charts in cancer-related mortalities, with... Read more

Microbiology

view channel
Image: The rapid MTB strip test for tuberculosis can identify TB patients within two hours (Photo courtesy of Chulalongkorn University)

Rapid MTB Strip Test Detects Tuberculosis in Less Than an Hour without Special Tools

Tuberculosis (TB), a highly infectious disease, continues to pose significant challenges to public health worldwide. TB is caused by a bacterium known as "Mycobacterium tuberculosis," spreading through... Read more

Pathology

view channel
Image: The UNIQO 160 (CE-IVDR) advances diagnostic analysis for autoimmune diseases (Photo courtesy of EUROIMMUN)

Novel Automated IIFT System Enables Cutting-Edge Diagnostic Analysis

A newly-launched automated indirect immunofluorescence test (IIFT) system for autoimmune disease diagnostics offers an all-in-one solution to enhance the efficiency of the complete IIFT process, comprising... Read more

Industry

view channel
Image: The global HbA1c testing devices market is expected to reach USD 2.56 billion in 2027 (Photo courtesy of Freepik)

Global Hemoglobin A1c Testing Devices Market Driven by Rising Prevalence of Diabetes

Hemoglobin A1c (HbA1c), or glycated hemoglobin, refers to hemoglobin with glucose attached. HbA1c testing devices are used for blood tests that determine average blood glucose, or blood sugar levels.... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.